Franklin Resources Inc. Sells 222,660 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Franklin Resources Inc. trimmed its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 15.9% during the 3rd quarter, Holdings Channel reports. The firm owned 1,177,195 shares of the company’s stock after selling 222,660 shares during the period. Franklin Resources Inc.’s holdings in Hims & Hers Health were worth $21,684,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after acquiring an additional 3,205,108 shares during the period. State Street Corp boosted its position in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after acquiring an additional 206,078 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after purchasing an additional 482,177 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after buying an additional 883,230 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after acquiring an additional 218,566 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $22.80.

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total transaction of $3,943,981.44. Following the completion of the transaction, the chief executive officer now owns 67,015 shares in the company, valued at $1,399,273.20. This represents a 73.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the sale, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. The trade was a 64.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,085,157 shares of company stock worth $26,765,193 over the last 90 days. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $26.36 on Friday. The stock’s 50-day moving average is $25.63 and its 200 day moving average is $21.23. Hims & Hers Health, Inc. has a 1-year low of $8.09 and a 1-year high of $35.02. The company has a market cap of $5.76 billion, a P/E ratio of 59.91 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue was up 77.1% compared to the same quarter last year. During the same period last year, the business earned ($0.04) EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.